[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunity":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,66,91,120,149,179,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100607502","phase-2-the-bloom-infant-probiotic-bip-study-100607502",false,"NCT07189390","The Bloom Infant Probiotic (BIP) Study","A Randomised Controlled Trial to Assess if a Probiotic Intervention Leads to Enhanced Immune Responses to Vaccination in Antibiotic-treated Infants (Bloom Infant Probiotic (BIP) Study)","BIP","Inclusion Criteria:\n\n1. Infants administered antibiotics in the first 28 days of life. Infants must have documented direct antibiotic exposure - defined as having received at least 36 hours of antibiotic treatment in the neonatal period (the first 28 days after birth).\n2. Gestational age ≥ 35 weeks.\n3. Birth weight ≥ 2500g.\n4. Mother aged at least 18 years and able and willing to provide written informed consent for themselves and their infant.\n5. Parent\u002Fguardian agrees to not give any other probiotics to their infant prior to vaccination at 6 weeks, including any formula that contains probiotics.\n6. Infant planning to receive all nationally approved vaccines during next 6 months.\n\nExclusion Criteria:\n\n1. Significant medical condition in either the mother or infant that, in the opinion of a medical investigator, may interfere with the study.\n2. Infant had confirmed sepsis or other serious infection in the neonatal period.\n3. Infants with known congenital diseases or who are immunocompromised or considered medically at risk (MAR).\n4. Infant participating in another interventional trial during the trial period.",true,"ALL","28 Days",{"count":21,"type":22},360,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to investigate whether administering a probiotic (Infloran®) to infants who received antibiotics in the first 28 days of life can restore or enhance their immune response to routine vaccines.\n\nAntibiotic use in the first weeks of life can lower the levels of beneficial gut bacteria, such as bifidobacteria, which play a key role in immune function. As a result, infants treated with antibiotics may produce fewer antibodies after routine vaccinations, leaving them less protected against infections.\n\nThe main questions this study aims to answer are:\n\n* Does treatment with the probiotic Infloran® improve the geometric mean concentrations (GMCs) of anticapsular antibodies against at least 11 serotypes included in the pneumococcal conjugate vaccine (PCV20) in serum samples collected at 6 months of age compared with placebo in infants treated with antibiotics in the neonatal period?\n* Does treatment with the probiotic Infloran® improve the GMCs for the pneumococcal conjugate vaccine (PCV20) at 12 months of age compared with placebo in infants treated with antibiotics in the neonatal period?\n* Does treatment with the probiotic Infloran® improve the GMCs of other routine childhood vaccines at 6 and 12 months of age compared with placebo in infants treated with antibiotics in the neonatal period?\n* Does treatment with the probiotic Infloran® increase the proportion of infants achieving seroprotective antibody levels for pneumococcal antigens compared to placebo in infants treated with antibiotics in the neonatal period?\n* What are the differences in antigen specific T cell responses, flow cytometry, blood transcriptomics, and gut microbiota composition in the probiotic (Infloran®) vs placebo groups in infants treated with antibiotics in the neonatal period?\n\nResearchers will compare infants who receive Infloran® (a probiotic containing Bifidobacterium bifidum and Lactobacillus acidphilus) with those who receive a placebo (which contains the same excipients as Infloran® but does not contain any bacterial strains).\n\nParticipants will:\n\n* Be randomly assigned to receive either a 14-day course of probiotic Infloran® or a placebo.\n* Provide blood samples (3-5 mL) at 6 weeks, 6.5 weeks (optional blood-draw for exploratory endpoint), 6 months and 12 months of age.\n* Provide stool samples at four timepoints: prior to starting the intervention (probiotic\u002Fplacebo), on day 7, on day 14 after completion of the study supplement, and prior to their first vaccination at 6 weeks of age.\n* Receive routine vaccinations at 6 weeks, 4 months and 6 months in line with the National Immunisation Program\n* Complete surveys to collect information regarding probiotic\u002Fplacebo administration and vaccination related side effects\n\nThis study aims to recruit 360 infants to assess whether this probiotic treatment following antibiotic exposure improves the immunogenicity of vaccinations. The information from this study will improve our understanding of how probiotic intervention can support optimal immune responses to vaccination in early life. The findings could potentially influence public health strategies, offering a new way to support optimal vaccine responses in antibiotic-treated infants.",[28,29,30,31,32],"Infant, Newborn","Immunity","Immunisation","Antibiotic Treatment","Microbiome Dysbiosis",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"infant","newborn","neonate","antibiotic","microbiome","microbiota","gut","probiotics","bifidobacteria","bifidobacterium","infloran","immunisation","immunity","immune system","vaccine","vaccination","immunization","randomised controlled trial","randomized controlled trial","RECRUITING","2026-05-24",{"date":56,"type":57},"2026-05-28","ACTUAL",{"date":59,"type":57},"2026-05-25",{"date":61,"type":22},"2029-10",{"name":63,"class":64},"South Australian Health and Medical Research Institute","OTHER",2,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":17,"sex":18,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100406989","understanding-immunity-to-the-flu-vaccine-in-covid-19-patients-100406989","NCT04579588","Understanding Immunity to the Flu Vaccine in COVID-19 Patients","Inclusion Criteria:\n\n* Age 9 through 64 years\n* Diagnosed with COVID-19 at least 2 months prior enrollment\n* Patients with or without obesity, diabetes, chronic fatigue and\u002For long term COVID-19 symptoms\n* Patients without COVID-19 diagnosis for controls\n\nExclusion Criteria:\n\n* Received the influenza vaccine less than 4 months ago\n* Pregnant or lactating\n* Patients with special risks attendant to venipuncture\n* Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment\n* Contraindication to the flu vaccine\n* Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement","9 Years","64 Years",{"count":75,"type":22},230,"OBSERVATIONAL","The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.",[79,80,29],"Corona Virus Infection","Flu Vaccine","2026-03-16",{"date":83,"type":57},"2026-03-18",{"date":85,"type":57},"2020-10-29",{"date":87,"type":22},"2028-04",{"name":89,"class":64},"Stanford University",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":17,"sex":18,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":90},"100533703","immune-and-cognitive-benefits-of-mango-intake-in-young-adults-100533703","NCT06229262","Immune and Cognitive Benefits of Mango Intake in Young Adults","Immune and Cognitive Benefits of Mango Intake in Young Adults: A Randomized Trial","Inclusion Criteria:\n\n* Male and female college students aged 18-30 years\n\nExclusion Criteria:\n\n* known intolerance or allergy to mangos\n* regular intake of mangos and\u002For fruits of a similar nutritional content such as peach, nectarine, papaya, apricot and cantaloupe\n* using cognition and\u002For immune-boosting supplements or vitamins\n* recent exposure to antibiotics and corticoids\n* uncontrolled chronic diseases and mental illnesses, clinical depression, and immunocompromised state","18 Years","30 Years",{"count":101,"type":22},54,[103],"NA","The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30 years",[106,29],"Cognition",[108,29,109],"Mango","cognition","NOT_YET_RECRUITING","2026-01-28",{"date":113,"type":57},"2026-01-30",{"date":115,"type":22},"2026-05",{"date":117,"type":22},"2026-12",{"name":119,"class":64},"Loma Linda University",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":90},"100619217","effects-of-bacillus-coagulans-snz-1969-on-immune-health-in-healthy-school-aged-children-100619217","NCT07341750","Effects of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children","A Randomized, Double-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children","BC SNZ 1969","Inclusion Criteria:\n\n* Males and females between 6 and 12 years of age at screening, inclusive.\n* Children enrolled in and attending school in person at baseline.\n* Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic and remote visits.\n* A care provider who can reliably bring the participant to study visits. The participant's primary caregiver must be willing and able to complete the questionnaires.\n* The participant or the participant's parents\u002Fguardian are willing and able to provide written assent and\u002For informed consent as appropriate.\n* Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study.\n* Healthy as determined by medical history as assessed by the Qualified Investigator (QI).\n\nExclusion Criteria:\n\n* Individuals who are pregnant.\n* Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of the investigational product or placebo ingredients.\n* History or presence of a clinically relevant cardiac, renal, hepatic, endocrine (including diabetes mellitus), respiratory, pulmonary, biliary, metabolic, haematologic, gastrointestinal, or pancreatic disorders, that may affect participation or outcomes as assessed by the QI.\n* Confirmed history of COVID-19 infection in the 3 months prior to baseline.\n* Immune dysfunction, autoimmune disease, immune compromised and\u002For taking an immunosuppressive medication, as assessed by the QI.\n* Severe environmental allergies requiring medical or need for allergy shots, as assessed by the QI.\n* Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI.\n* Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable.\n* Asthma, as assessed by the QI.\n* Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and or safety of the investigational product.\n* Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI.\n* Participant or participant's caregiver who are cognitively or neurodevelopmentally impaired affecting their ability to give informed consent and\u002For assent.\n* Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant.","6 Years","12 Years",{"count":131,"type":22},100,[103],"The goal of this clinical trial is to investigate the safety and efficacy of Bacillus coagulans SNZ 1969 on immune health in healthy school-aged children in terms of reduction of respiratory symptoms, gastrointestinal symptoms, immunoglobulins, immune biomarkers and fecal microbiome changes.\n\nThe current study will examine the efficacy of Bacillus coagulans SNZ 1969 (B. coagulans) on immune health in children attending school. The primary outcome will assess the difference between the investigational product and placebo from baseline to day 84 in incidence, duration, and severity of Upper Respiratory Tract Infection (URTI) and Gastrointestinal Tract Infection (GITI) symptoms. This will be assessed by use of the Canadian Acute Respiratory Illness and Flu Scale (CARIFS) and a GITI symptoms questionnaire.\n\nEnrolled participants will include children 6-12 years of age currently attending school during the 2025-2026 cold and flu season to allow for adequate exposure to URTI or GITI pathogens. To avoid confounding effects of pre-existing medical conditions children presenting with a history or presence of a clinically relevant respiratory, pulmonary, or gastrointestinal condition will be excluded at the discretion of the Qualified Investigator. Furthermore, participants consuming immune modulating medications, antibiotics, products containing B. coagulans, or any other probiotic supplement will be excluded unless they have undergone the specified washout. The strict eligibility criteria is designed to reduce confounders on immune health affecting both upper respiratory tract infections and gastrointestinal tract infection symptoms. Children presenting with any other medical condition or lifestyle factor which may affect the safety of their participation or study outcomes will also be excluded.\n\nEach participant will be assigned a randomization code according to the order of the randomization list generated. Enrolled participants will be randomized to the different study arms at Day 0. Participants will take either probiotic Bacillus coagulans SNZ 1969 or a placebo every day for 84 days.\n\nDay 0 (Baseline, Visit 2) Eligible volunteers will return to the clinic for baseline assessments with collected stool and saliva samples.\n\nBaseline (Day 0) assessments include:\n\n1. Review concomitant therapies (inclusive of previous vaccinations) and current health status\n2. Assess inclusion and exclusion criteria\n3. Review any pre-emergent AEs\n4. Urine pregnancy test for potential volunteers that are of child-bearing potential\n5. Vital sign measurements (BP and HR)\n6. Weight and height measurements\n7. Randomization of eligible participants\n8. Collect blood samples for analysis of:\n\n   1. Quantibody® Human Immune Response Array\n   2. Immunoglobulins A (IgA), G (IgG), E (IgE) and M (IgM) serum levels\n9. Collect saliva sample for the analysis of Salivary Ig A Levels\n10. Collect stool samples for microbiome analysis\n11. Review completed study diaries including CARIFS, Additional respiratory tract symptoms, and GITI symptoms questionnaires\n12. Dispense investigational product and instruct participants on use\n13. Dispense study diary inclusive of the CARIFS, Additional respiratory tract symptoms, and GITI symptoms questionnaires\n14. Dispense stool collection kit for microbiome analysis for Visit 5 (End of Study visit)\n15. Dispense saliva collection kit for Visit 5 (End of Study visit) The next visit will be conducted remotely and scheduled for Day 28 (± 2 days) and Day 56 (± 2 days).\n\nEnd of Study (Day 84 ± 2 days):\n\nParticipants will return to the clinic for end of study assessments, with unused investigational product, completed study diaries (inclusive of the CARIFs, Additional respiratory tract symptoms, and GITI symptoms questionnaires), and stool and saliva samples.\n\nVisit 5 assessments include:\n\n1. Return and review study diary\n2. Return unused investigational product in the original packaging and remnants and calculate compliance by counting the returned unused investigational product\n3. Review concomitant therapies and AEs\n4. Vital sign measurements (BP and HR)\n5. Weight and height measurements\n6. Urine pregnancy test for participants that are of childbearing potential\n7. Collect blood samples for the analysis of:\n\n   1. Quantibody® Human Immune Response Array\n   2. Immunoglobulins A (IgA), G (IgG), E (IgE) and M (IgM) serum levels\n8. Collect saliva samples for the analysis of Salivary Ig A Levels\n9. Collect stool samples for microbiome analysis\n10. Review completed study diaries including CARIFS, Additional respiratory tract symptoms, and GITI symptoms questionnaires",[29],[136,137,138],"Probiotic immune health","Bacillus coagulans","Bacillus coagulans SNZ 1969","2026-01-06",{"date":141,"type":57},"2026-01-14",{"date":143,"type":57},"2025-11-05",{"date":145,"type":22},"2026-05-31",{"name":147,"class":148},"Sanzyme Biologics Private Limited","INDUSTRY",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":17,"sex":157,"minAge":98,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":90},"100598972","innate-immunity-microbiota-and-inovative-treatments-in-endometriosis-100598972","NCT07078435","Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis","Inflammation, Innate Immunity, MIcrobiota and Inovative Treatments in ENDOmetriosis","IMIEndo","Inclusion Criteria:\n\n* Women aged 18-42 years.\n* Surgery scheduled during the luteal phase.\n* Written informed consent provided.\n\nAdditional inclusion criteria for the \"endometriosis\" group:\n\n* Women with confirmed endometriosis and a surgical indication (due to persistent symptoms despite medical treatment and\u002For risk of organ damage).\n* Hormonal therapy discontinued at least one month prior to surgery.\n* Absence of isolated ovarian endometrioma.\n\nControl group inclusion criteria:\n\n\\- Women requiring benign gynecological surgery with no clinical or intraoperative evidence of endometriosis.\n\nNo inclusion criteria (both groups):\n\n* Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other autoimmune disorders (e.g., lupus, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis, spondyloarthritis),\n* Use of antibiotics within the month prior to surgery,\n* Recent infection (\\\u003C2 weeks),\n* Ongoing treatment with biologics or immunosuppressants,\n* Contraindication to surgery due to general condition or comorbidities,\n* Hormonal therapy within the month prior to surgery,\n* Abdominopelvic surgery involving peritoneal breach within the previous 6 months,\n* Pregnancy or breastfeeding,\n* Participation in another clinical study (RIPH 1 or 2).\n\nExclusion Criteria:\n\n* Intraoperative impossibility to perform surgery due to local conditions with an unfavorable benefit-risk balance for the patient.\n* Discovery of endometriosis during surgery in the control group.\n* Use of biologics or immunosuppressants within the first year after inclusion in the endometriosis group.\n* Antibiotic use in the month preceding the second stool sample (endometriosis group).","FEMALE","42 Years",{"count":160,"type":22},40,[103],"Endometriosis is a chronic inflammatory, polygenic, and multifactorial disease affecting approximately 10% of women of reproductive age, corresponding to over one million women in France. Endometriosis profoundly impairs the health and quality of life of affected individuals and carries a significant socio-economic burden, making it a major public health concern. To date, the pathogenesis and prognostic factors of disease progression remain poorly understood. Despite current treatment options, which are based on hormonal therapy or surgery, resistance and recurrence are frequent, underscoring the urgent need for innovative therapeutic strategies.\n\nThe hypothesis of retrograde menstruation of endometrial cells, among other proposed theories, appears insufficient to fully explain the development of the disease. Immunological factors may be implicated. Endometriosis is characterized by the presence of endometriotic tissue outside the uterine cavity- within the peritoneal cavity or at distant sites-forming lesions that, like eutopic endometrium, contain infiltrating immune cells, with varying compositions across menstrual cycle phases. Although data remain scarce, the literature points to several key mechanisms:\n\nInflammation and innate immunity with the dendritic cells, that initiate and orchestrate immune responses, appear to be present in different proportions and exhibit altered phenotypes in endometriotic tissue compared to healthy tissue. Macrophages, essential for phagocytosis, tissue repair, and the resolution of inflammation, also show functional and phenotypic modulation. In particular, efferocytosis-their ability to clear apoptotic cells-is impaired, and an imbalance in M1\u002FM2 polarization has been described, potentially facilitating menstrual cell escape. The local microenvironment is characterized by altered cytokine and chemokine profiles. Natural Killer cells exhibit disrupted expression patterns of activating and degranulation capacity.\n\nMicrobiota: Many studies suggest a potential role for the intestinal microbiota in the initiation and\u002For promotion of endometriosis. Patients frequently exhibit gut dysbiosis, marked by reduced microbial diversity.\n\nResolution of Inflammation: Endometriosis may be associated with defective resolution of inflammation. Resolutive pharmacology involves the use of pro-resolving factors to exert a therapeutic effect by accelerating or stimulating the resolution of inflammation.\n\nThe interplay between local inflammation, the gut microbiota, and disease progression remains incompletely elucidated. A comprehensive phenotypic and functional characterization of immune cells-particularly innate immune cells (dendritic cells, macrophages, Natural Killer cells) - in parallel with microbiome profiling and clinical outcome data, may yield novel insights into disease mechanisms and support the development of pro-resolutive therapeutic strategies that may be of interest in endometriosis.\n\nStudy Design This will be a monocentric (at Grenoble University Hospital), open-label, prospective experimental study with a control arm.\n\nThe primary objective is to identify immune biomarkers associated with endometriosis.\n\nSecondary objectives include:\n\n1. Identification of immune biomarkers associated with clinical outcomes in endometriosis.\n2. Characterization of the immunogenetic KIR\u002FHLA (Killer Immunoglobulin-like Receptors \u002F Human Leukocyte Antigen) system in both study groups.\n3. Analysis of stromal cells, apoptosis, macrophage efferocytosis, and their responsiveness to pro-resolutive factors in both groups.\n4. Identification of a characteristic bacterial gut microbiota profile at diagnosis in women with endometriosis versus controls, and\u002For profiles associated with one-year clinical outcomes (favorable vs unfavorable), as well as temporal microbiota trajectories over one year in relation to clinical response.\n\nStudy Population:\n\nThe study will include women undergoing surgery for endometriosis versus control women undergoing benign gynecological surgery with no known history or intraoperative evidence of endometriosis, aged 18 to 42.\n\nStudy Procedures:\n\nWomen in the endometriosis group will undergo collection of endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage. For both groups, peripheral blood samples will be collected during routine care and stool samples obtained at baseline (Day 0). For the endometriosis group, a second stool sample will be collected at 12 months (M12).\n\nA clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery, whereas endometriosis group subjects will be followed for 12 months.",[164,29,165],"Endometriosis","Microbiota",[167,168,46,169,39],"endometriosis","surgery","efferocytose","2025-08-25",{"date":172,"type":57},"2025-09-02",{"date":174,"type":22},"2025-09-09",{"date":176,"type":22},"2027-09-30",{"name":178,"class":64},"University Hospital, Grenoble",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":17,"sex":18,"minAge":98,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100600090","comparison-of-the-effects-of-aerobic-anaerobic-exercises-on-hormonal-and-immune-biomarkers-100600090","NCT07092969","Comparison of the Effects of Aerobic-Anaerobic Exercises on Hormonal and Immune Biomarkers","Comparison of the Effects of Aerobic and Anaerobic Exercises on Hormonal and Immune Biomarkers Measured by Blood and Saliva in Young Individuals","Biomarkers","Inclusion Criteria:\n\n* Being a university student,\n* Being between the ages of 18 and 25.\n\nExclusion Criteria:\n\n* Having orthopedic problems that prevent exercise,\n* Having cognitive or mental health problems that prevent participation in exercise,\n* Having chronic systemic diseases such as cardiac, pulmonary, or nephrological.","25 Years",{"count":189,"type":22},90,[103],"This study aims to compare the effects of aerobic and anaerobic exercise on hormonal, immunological, and metabolic biomarkers in young individuals using blood and saliva samples. It will also assess participants' physical activity levels, depression levels, and general lifestyle habits to explore their relationship with biomarker profiles. Biomarkers such as testosterone, progesterone, cortisol, IgA, alpha-amylase, insulin, lactate, and various inflammatory cytokines will be measured using ELISA. The study seeks to evaluate the physiological and psychosocial effects of different types of exercise in a holistic manner.",[193,185,194,29],"Activity, Motor","Exercise",[196,197,198,199],"Exercise physiology","Aerobic and anaerobic exercis","Hormonal and immunological responses","Physical activity","2025-07-28",{"date":202,"type":57},"2025-07-30",{"date":204,"type":22},"2025-09-15",{"date":206,"type":22},"2026-09-15",{"name":208,"class":64},"Sakarya Applied Sciences University",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":17,"sex":18,"minAge":98,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":90},"100542028","precision-psychiatry-for-depression-immune-response-and-affective-symptoms-as-predictors-of-response-to-antidepressants-100542028","NCT06337539","Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants","LYMPHODEP","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Clinical diagnosis of major depression according to DSM-5 criteria made by a psychiatrist applying the Structured Clinical Interview for DSM-5 (SCID-5).\n* Eligible for receiving antidepressant treatment for major depression.\n\nExclusion Criteria:\n\n* Who have received antidepressant, antipsychotic or euthymizer treatments in the 6 weeks prior to inclusion in the study.\n* Who present concurrent psychotic symptoms.\n* Who present disorders due to alcohol or drug use, with active consumption during the last 3 months.\n* Pregnant women.\n* Who have serious or unstable medical disorders, Addison's or Cushing's disease, systemic inflammatory or autoimmune diseases, or primary or secondary immunodeficiencies.","65 Years",{"count":218,"type":22},50,"Objectives: To identify in patients with major depression different peripheral markers of neuroinflammation in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and its relationship with the response to antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs).\n\nMethodology: This is a prospective observational cohort study in patients with major depression naturally subjected to treatment with SSRIs. For this, 30 patients with major depression attended in the Outpatient Psychiatry Consultations will be selected. All of them will be evaluated at baseline and after 3 months of treatment, collecting demographic and clinical variables, Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) psychiatric diagnoses, psychopathological scales and immunological and biochemical variables. The correlation between immunological markers and affective and cognitive symptoms at baseline, as well as their variation with treatment, will be analyzed. A group of 20 healthy subjects will be used as a control group.\n\nSubsequently, a bivariate comparative analysis will be carried out, where the statistically significant or marginally significant variables associated with psychopathological variables will be used to build a multivariate binary logistic regression model.",[221,222,223,29],"Depression","Inflammation","Antidepressants",[225,221,222,29],"Selective serotonin reuptake inhibitors","2024-03-22",{"date":228,"type":57},"2024-03-29",{"date":230,"type":22},"2024-04-01",{"date":232,"type":22},"2027-07-31",{"name":234,"class":64},"Germans Trias i Pujol Hospital"]